ECOR icon

electroCore

6.81 USD
-0.35
4.89%
At close Mar 27, 4:00 PM EDT
After hours
6.81
+0.00
0.00%
1 day
-4.89%
5 days
-14.88%
1 month
-56.12%
3 months
-58.63%
6 months
0.89%
Year to date
-59.39%
1 year
16.01%
5 years
12.56%
10 years
-97.71%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

101% more capital invested

Capital invested by funds: $7.15M [Q3] → $14.4M (+$7.25M) [Q4]

39% more funds holding

Funds holding: 23 [Q3] → 32 (+9) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

9.97% less ownership

Funds ownership: 23.49% [Q3] → 13.52% (-9.97%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$25
267%
upside
Avg. target
$26
274%
upside
High target
$26
282%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Ladenburg Thalmann
Jeffrey Cohen
50% 1-year accuracy
1 / 2 met price target
282%upside
$26
Buy
Maintained
13 Mar 2025
HC Wainwright & Co.
Swayampakula Ramakanth
23% 1-year accuracy
46 / 198 met price target
267%upside
$25
Buy
Reiterated
13 Mar 2025

Financial journalist opinion

Based on 5 articles about ECOR published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Tyler Bussian - Brookline Capital Operator [Call Starts Abruptly] As part of our ongoing efforts to reduce costs and drive profitability, management has opted to host this earnings call on Zoom rather than using a more costly service provider. This will be our first time hosting the call independently, so we appreciate your patience as we work through any potential technical issues.
electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
electroCore Announces Full Year 2024 Financial Results
Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM   in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in Truvaga TM   sales
electroCore Announces Full Year 2024 Financial Results
Neutral
GlobeNewsWire
3 weeks ago
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
Neutral
GlobeNewsWire
3 weeks ago
electroCore to Participate at Upcoming Investor Conferences
Management to Attend the 37th Annual Roth Conference and the LSI USA '25 Management to Attend the 37th Annual Roth Conference and the LSI USA '25
electroCore to Participate at Upcoming Investor Conferences
Neutral
GlobeNewsWire
4 weeks ago
electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal
ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomedical, an FDA cleared non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities.
electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal
Positive
Zacks Investment Research
1 month ago
electroCore (ECOR) Is a Great Choice for 'Trend' Investors, Here's Why
electroCore (ECOR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
electroCore (ECOR) Is a Great Choice for 'Trend' Investors, Here's Why
Neutral
GlobeNewsWire
1 month ago
electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12, 2025 in Snowbird, Utah.
electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Positive
Zacks Investment Research
1 month ago
Here's Why Momentum in electroCore (ECOR) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, electroCore (ECOR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Momentum in electroCore (ECOR) Should Keep going
Positive
Seeking Alpha
2 months ago
electroCore: An Opportunity In Medical And Wellness Device Innovation
electroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headaches, and expanding product lines indicate strong potential and barriers to entry. Management is focused on profitability, rather than international expansion, with high gross margins and decreasing OPEX as a percentage of revenue.
electroCore: An Opportunity In Medical And Wellness Device Innovation
Positive
Seeking Alpha
2 months ago
electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM
electroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifying with the rugged TAC-STIM for military use and the consumer-focused Truvaga Plus, targeting wellness markets. The recent acquisition of NeuroMetrix's Quell system for fibromyalgia offers revenue and cost synergies, leveraging electroCore's established sales channels.
electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM
Charts implemented using Lightweight Charts™